(Q45419941)

14 December 2017

title

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma (English)

1 reference

14 December 2017

1 reference

1 reference

1 reference

Yu-Hong Li

1

1 reference

14 December 2017

Yi-Fu He

2

1 reference

14 December 2017

Wen-Qi Jiang

3

1 reference

14 December 2017

Fen-Hua Wang

4

1 reference

14 December 2017

Xu-Bin Lin

5

1 reference

14 December 2017

Li Zhang

6

1 reference

14 December 2017

Zhong-Jun Xia

7

1 reference

14 December 2017

Xiao-Fei Sun

8

1 reference

14 December 2017

Hui-Qiang Huang

9

1 reference

14 December 2017

Tong-Yu Lin

10

1 reference

14 December 2017

You-Jian He

11

1 reference

14 December 2017

Zhong-Zhen Guan

12

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

14 December 2017

number of pages

6

1 reference

inferred from page(s)

published in

Cancer

1 reference

14 December 2017

volume

106

1 reference

14 December 2017

issue

6

1 reference

14 December 2017

page(s)

1320-1325

1 reference

Prevention and control of hepatitis B in China

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Letter: Subacute and chronic active hepatitis after withdrawal of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

Hepatitis B infection in patients with lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21701

7 January 2021

Identifiers

DOI

10.1002/CNCR.21701

1 reference

14 December 2017

1 reference